---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-002729"
form_type: "8-K"
ticker: "MIRA"
cik: "0001904286"
company_name: "MIRA PHARMACEUTICALS, INC."
filed_at: "2024-01-17T23:59:59+00:00"
generated_at: "2026-06-06T22:46:13.001274+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Director and part-time General Counsel Christos Nicholoudis resigns

## Summary
- Christos Nicholoudis resigned from the Board and as part-time General Counsel effective January 15, 2024.
- Resignation did not involve disagreements with the Company, management, or Board.
- No replacement for the director or General Counsel role announced in the filing.

## SEC filing metadata
- accession: 0001493152-24-002729
- form_type: 8-K
- ticker: MIRA
- cik: 0001904286
- company_name: MIRA PHARMACEUTICALS, INC.
- filed_at: 2024-01-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1904286/000149315224002729/0001493152-24-002729-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1904286/000149315224002729/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-002729
- JSON: https://secwatch.observer/filing/0001493152-24-002729.json
- Plain text: https://secwatch.observer/filing/0001493152-24-002729.txt

## Key facts
- Executive change
  Christos Nicholoudis resigned as Director and part-time General Counsel at MIRA PHARMACEUTICALS, INC..
  - Action: resigned
  - Role: Director and part-time General Counsel
  source text: On January 15, 2024, Christos Nicholoudis, Esq. resigned from the Board of Directors of the Company and as part-time General Counsel of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1904286/000149315224002729/0001493152-24-002729-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.